ArticleJournal of comparative effectiveness research2023

Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.

Jun Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.